In the STEP-HFpEF trial, 2.4 mg semaglutide produced marked improvements in heart failure-related symptoms, physical limitations, and exercise function, and reduced inflammation and body weight in individuals with obesity HFpEF phenotype. These data usher in a new paradigm of targeting obesity as a therapeutic strategy in HFpEF.
Authors
Verma, Subodh; Borlaug, Barry A; Butler, Javed; Davies, Melanie J; Kitzman, Dalane W; Petrie, Mark C; Shah, Sanjiv J; Dhingra, Nitish K; Kosiborod, Mikhail N